May 8 2012 Issue

1) A case of Necrotizing myopathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Mammen interviews Prof. Michael Hanna about his paper on necrotizing myopathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about unilateral clubbing in hemiplegia. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of Alzheimer disease. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Mammen has served as an expert witness for trials in 2010 and 2011; receives revenue for a patent on anti-HMGCR antibody detection technology; and received honoraria for Grand Round presentations at several universities.Prof. Hanna receives research funding from the Medical Research Council, MRC Center grant (G0601943), from the Muscular Dystrophy Campaign and the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) NIH grant U54 NS059065. M.G. Hanna provides the UK national patient referral center for skeletal muscle channelopathies funded by the UK Department of Health National Commissioning Group. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.